Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment

Agnieszka Lawrenczyk; Seil Kim; Xiangshu Wen; Ran Xiong; Weiming Yuan

doi:10.3390/pathogens3030563

Exploring the Therapeutic Potentials of iNKT Cells for Anti-HBV Treatment

Pathogens. 2014 Jul 3;3(3):563-76. doi: 10.3390/pathogens3030563.

Authors

Agnieszka Lawrenczyk¹, Seil Kim², Xiangshu Wen³, Ran Xiong⁴, Weiming Yuan⁵

Affiliations

¹ Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. alawrenczyk@calibr.org.
² Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. seilkim@usc.edu.
³ Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. xiangshw@usc.edu.
⁴ Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. rxiong@usc.edu.
⁵ Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. weiming.yuan@usc.edu.

Abstract

CD1d-restricted invariant NKT (iNKT) cells are a group of innate-like regulatory T cells that recognize lipid antigens. Both mouse modeling experiments and human clinical studies have suggested a key role for iNKT cells in anti-HBV immunity and these potent T cells can be explored as a novel therapeutic target for anti-HBV treatment. We aim to humanize mice in the CD1d/iNKT cell lipid presentation system and provide new research tools for identifying novel anti-HBV agents.

Publication types

Review

Grants and funding

R01 AI091987/AI/NIAID NIH HHS/United States